Drug intelligence / Profile preview

nicotinamide 8-bromo-adenine dinucleotide phosphate

Development stage
Unknown
Modality
Small Molecules
01

Overview

Nicotinamide 8-bromo‐adenine dinucleotide phosphate (NA8BrADP) is a synthetic analog of nicotinamide adenine dinucleotide phosphate (NADP+), which is an essential cofactor in many enzymatic redox reactions. The compound features a brominated adenine moiety at the eighth position. As an NADP+ analog and member of the (5'→5')‐dinucleotides class of organic compounds, it may be used experimentally to probe or modulate NADP+-dependent biochemical pathways or enzyme activities. There are no approved therapeutic indications for this molecule; it is classified as experimental and primarily used in research settings[1][2][3].

Other names
Nicotinamide 8-bromo-adenine dinucleotide phosphateNicotinamide8-bromo-adenine dinucleotide phosphateNicotinamide-8-bromo-adenine dinucleotide phosphate[(2R,3R,4R,5R)-5-(6-amino-8-bromopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl][(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan -2 -yl]methyl phosphate(((2R,3R,4R,5R)-5-(6-amino–8-bromopurin–9–yl)–3–hydroxy–4-phosphonooxyoxolan–2–yl)methoxy-hydroxyphosphoryl)((2 R , 3 S , 4 R , 5 R ) – 5 – ( 3 – carbamoylpyridin –1 –ium –1 – yl ) – 3 , 4-dihydroxyoxolan -2 - yl ) methyl phosphate

Beyond the preview

Go deeper on nicotinamide 8-bromo-adenine dinucleotide phosphate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicotinamide 8-bromo-adenine dinucleotide phosphate.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call